title: Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation.
abstract: The gastrointestinal tract is structurally and functionally different from the vagina. Thus, the paradigm of topical microbicide development and evaluation has evolved to include rectal microbicides (RMs). Our interest was to create unique RM formulations to safely and effectively deliver antiretroviral drugs to mucosal tissue. RMs were designed to include those that spread and coat all surfaces of the rectum and distal colon rapidly (liquid) and those that create a deformable, erodible barrier and remain localized at the administration site (gel). Tenofovir (TFV) (1%) was formulated as an aqueous thermoreversible fluid and a carbopol-based aqueous hydrogel. Lipid-based liquid and gel formulations were prepared for UC781 (0.1%) using isopropyl myristate and GTCC (Caprylic/Capric Triglycerides), respectively. Formulations were characterized for pH, viscosity, osmolality, and drug content. Pre-clinical testing incorporated ex vivo colonic tissue obtained through surgical resections and flexible sigmoidoscopy (flex sig). As this was the first time using tissue from both sources side-by-side, the ability to replicate HIV-1 was compared. Efficacy of the RM formulations was tested by applying the products with HIV-1 directly to polarized colonic tissue and following viral replication. Safety of the formulations was determined by MTT assay and histology. All products had a neutral pH and were isoosmolar. While HIV-1BaL and HIV-1JR-CSF alone and in the presence of semen had similar replication trends between surgically resected and flex sig tissues, the magnitude of viral replication was significantly better in flex sig tissues. Both TFV and UC781 formulations protected the colonic tissue, regardless of tissue source, from HIV-1 and retained tissue viability and architecture. Our in vitro and ex vivo results show successful formulation of unique RMs. Moreover, the results of flex sig and surgically resected tissues were comparable suggesting the incorporation of both in pre-clinical testing algorithms.
authors.affiliation: Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America; Department Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Charlene S
authors.initials: CS
authors.lastname: Dezzutti
authors.affiliation: Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Julie
authors.initials: J
authors.lastname: Russo
authors.affiliation: Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Lin
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Medicine, Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Kaleab Z
authors.initials: KZ
authors.lastname: Abebe
authors.affiliation: Department of Medicine, Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Jie
authors.initials: J
authors.lastname: Li
authors.affiliation: CONRAD, Arlington, Virginia, United States of America.
authors.forename: David R
authors.initials: DR
authors.lastname: Friend
authors.affiliation: Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Ian M
authors.initials: IM
authors.lastname: McGowan
authors.affiliation: Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America; Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
authors.forename: Lisa C
authors.initials: LC
authors.lastname: Rohan
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D000328:Adult; D000813:Anilides / Q000494:pharmacology* / Q000633:toxicity; D000891:Anti-Infective Agents, Local / Q000494:pharmacology* / Q000633:toxicity; D003106:Colon / Q000187:drug effects / Q000821:virology; D004353:Drug Evaluation, Preclinical; D004355:Drug Stability; D005663:Furans / Q000494:pharmacology* / Q000633:toxicity; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D020100:Hydrogels; D008875:Middle Aged; D063065:Organophosphonates / Q000494:pharmacology* / Q000633:toxicity; D012661:Semen / Q000502:physiology; D000068698:Tenofovir; D013854:Thioamides; D014779:Virus Replication / Q000187:drug effects*; D055815:Young Adult
chemical_list: D000813:Anilides; D000891:Anti-Infective Agents, Local; D005663:Furans; D020100:Hydrogels; D063065:Organophosphonates; D013854:Thioamides; D000068698:Tenofovir; D000225:Adenine; C100668:UC-781